Smart Money Circle

This Sustainable Food CEO Wants To Help You Eat Better. Meet John Keeler Founder & CEO Of Blue Star Foods, $BSFC

Company: Blue Star Foods

Ticker: $BSFC

Website: https://bluestarfoods.com/

John’s Bio:

John Keeler Founder & CEO Founded BSFC in 1995; successfully built sales over the past 26 years to $20+ million annually and is recognized as a leader and innovator in the measurable ESG enterprise model within the seafood industry. BS in Economics from Rutgers University; attended Harvard Business School Executive Programs focused on supply chain management, negotiations and marketing. Named Best CEO in Sustainable Seafood Industry by European CEO Magazine. 2017 Speaker at “The Economist World Ocean Summit”.

Company Profile

Blue Star Foods Corp., an international seafood company, processes, imports, packages, and sells refrigerated seafood products. It offers pasteurized crab meat, and other seafood products, under the Blue Star, Pacifika, Oceanica, Crab & Go Premium Seafood, Lubkin, First Choice, Good Stuff, and Coastal Pride Fresh brands. The company sells its products to food service distributors, wholesalers, retail establishments, and seafood distributors in the United States, Canada, and Europe. Blue Star Foods Corp. was formerly known as John Keeler & Co. Inc. Blue Star Foods Corp. was founded in 1995 and is headquartered in Miami, Florida. Blue Star Food Corp. (Nasdaq: BSFC) seeks to enhance shareholder value not only through exceptional business performance and practices, but also through responsible and effective communication with its shareholders. The latest company information relevant to the individual and institutional investor includes stock price and history, upcoming events and presentations and financial documents. Blue Star Foods is traded on the Nasdaq under the ticker symbol $BSFC.

Learn more here:

https://bluestarfoods.com/

This Biotech CEO Has a Unique Approach To Fight Cancer. Cel-Sci Corp CEO - $CVM

Guest: Geert Kersten CEO of CEL SCI Corp $CVM

Ticker: $CVM

Website: https://cel-sci.com/

Geert Kersten Biography

Geert Kersten has served in his current leadership role as Chief Executive Officer at CEL-SCI Corporation (NYSE American: CVM) since 1995 and has been with CEL-SCI since 1987. He has been involved in the pioneering field of cancer immunotherapy for over three decades and has successfully steered CEL-SCI through many challenging cycles in the biotechnology industry. Mr. Kersten also provides CEL-SCI with significant expertise in the fields of finance and law and has a unique vision of how CEL-SCI's Multikine product could potentially change the way cancer is treated. Prior to joining CEL-SCI, Mr. Kersten worked at the law firm of Finley & Kumble and worked at Source Capital. Mr. Kersten received his Undergraduate Degree in Accounting and an M.B.A. from George Washington University, and a law degree (J.D.) from American University in Washington, DC.

Investors Can Learn More:

https://cel-sci.com/new-investor-information/

Guest: Dr. Shankar Musunuri - Ocugen, Chairman, Chief Executive Officer, and Co-founder

Website:

www.ocugen.com

Ticker: OCGN

Bio:

Dr. Shankar Musunuri is Chairman, CEO and Co-Founder of Ocugen. The company (NASDAQ: OCGN) is a publicly traded biotechnology company focused on discovery, development, commercialization of gene therapies, cell therapies, biologicals, and vaccines, based in Malvern, Pennsylvania. Dr. Musunuri transformed Ocugen from a start-up into a cutting-edge science-based biotech powerhouse with three distinct first-in-class platform technologies focused on ophthalmology with a first-in-class modifier gene therapy platform targeting rare as well as large blindness diseases, orthopedics with a regenerative cell therapy platform, and infectious diseases with an inhalation vaccine platform targeting Covid-19, flu, and a combination vaccine for both COVID-19 and flu. Ocugen anticipates launching products from these game-changing platform technologies within the next few years. The company’s mission is to develop cutting-edge innovations for people with serious diseases and conditions with a commitment to ensuring global market access.

Dr. Musunuri is a seasoned biotech veteran with 30+ years’ experience advancing and commercializing a diverse portfolio of products. Prior to co-founding Ocugen in 2013, he held leadership roles at numerous companies ranging from large multinational biotechnology companies such as Wyeth and Pfizer, to novel start-up biotech companies. During his 15 years at Pfizer, he gained extensive product launch and life-cycle management experience including leading the Global Operations Team for Prevnar 13, the world’s best-selling vaccine. Dr. Musunuri then founded Nuron Biotech, Inc., which grew into a commercial company in less than three years.

Dr. Musunuri obtained his PhD in Pharmaceutical Sciences from the University of Connecticut—where he also received a Distinguished Alumnus Award. He also received an MBA from Duke University, where today he serves on the University’s Innovation & Entrepreneurship Board of Advisors. Dr. Musunuri serves as both CEO and Chairman of the board of Ocugen. He has received numerous leadership awards including Most Admired CEO Award by Philadelphia Business Journal, the 2023 Healthcare Power 100 (ranked 22nd) in PA and the 2023 AAPI Power 100 (ranked 11th) in PA. He is also a Board Member of the Musunuri Family Foundation, a non-profit that provides college scholarships for high school students. Dr. Musunuri has a passion for addressing diseases and conditions which lack effective treatments. This commitment is reflected in Ocugen’s mission of relentlessly pursuing courageous innovation on behalf of patients with unmet medical needs.

About Ocugen, Inc.

Ocugen, Inc. is a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines that improve health and offer hope for patients across the globe. We are making an impact on patients’ lives through courageous innovation—forging new scientific paths that harness our unique intellectual and human capital. Our breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with a single product, and we are advancing research in infectious diseases to support public health and orthopedic diseases to address unmet medical needs.

Discover more at www.ocugen.com

Conor McGregor Invested in this MMA Stock. Meet Nick Langton Founder & CEO Alta Global Ticker $MMA

Conor McGregor Invested in this MMA Stock. Meet Nick Langton Founder & CEO Alta Global Ticker $MMA

Guest:

Nick Langton Founder & CEO Alta Global

Ticker $MMA

Website:

trainalta.com

ABOUT ALTA GLOBAL GROUP LIMITED

Alta Global Group Limited is a technology company that is seeking to increase consumer participation in martial arts and combat sports whilst building upon existing community offerings within the sector. Alta currently has three business units designed to provide services to and monetize all key stakeholders in the sector, namely fans, participants, coaches, gym owners and athletes.

· TrainAlta (www.trainalta.com) partners with gyms and coaches to deliver a range of consumer products that drive participation in martial arts for fans and beginners.

· Hype (www.hype.co) is a mobile marketing platform designed to help gym owners, coaches and athlete partners grow revenue from their followers and audiences in today's age of social media.

· MixedMartialArts.com (www.mixedmartialarts.com) is a leading platform for the MMA community, providing access to MMA news and media, fighter data, fight schedules and access to the legendary Underground forum.

For further information about Alta Global Group Limited (NYSE American: MMA), please visit www.altaglobalgroup.com

Follow us on social media via Facebook, X, Instagram, or LinkedIn @trainalta.

Guest: 
John Cash CEO and Chairman of the Board for Ur-Energy Inc. Ticker: URG

Forget Ozempic & Wegovy. The Biggest Opportunity In Weight Loss Today. Lose Weight, Not Muscle $VERU

Guest:

* CEO: Dr. Mitchell Steiner

* Title: Founder, Chairman, CEO, and President

* Website: www.verupharma.com

* Ticker: NASDAQ: Veru

* Bio:

Mitchell S. Steiner, M.D., F.A.C.S. has served as President and Chief Executive Officer of Veru and as a director of the Company since October 2016. Dr. Steiner was the co-founder of Aspen Park and served as Aspen Park's Chief Executive Officer, President and Vice Chairman of the Board from July 2014 to October 2016. From 2014 to 2016, Dr. Steiner was a consultant and then the President, Urology and member of senior management of OPKO Health, Inc. (NYSE:OPK) and had responsibilities for the launch, marketing, sales and reimbursement of 4Kscore prostate cancer test to urologists and primary care physicians. Dr. Steiner was also the co-founder of GTx, Inc., a men's health and oncology public company, where he served as Chief Executive Officer and Vice Chairman of Board of Directors from 1997 to 2014. Dr. Steiner is a Board Certified Urologist and a Fellow of the American College of Surgeons and has held numerous academic appointments, including Assistant Professor of Urology, Cell Biology, and Pathology at Vanderbilt School of Medicine from 1993 to 1995 and Chairman and Professor of Urology, Director of Urologic Oncology and Research and the Chair of Excellence in Urologic Oncology at the University of Tennessee from 1995 to 2004. Dr. Steiner holds a B.A. in Molecular Biology and Chemistry from Vanderbilt University and an M.D. from the University of Tennessee. He performed his surgical and urologic training at The Johns Hopkins Hospital and postdoctoral research fellow in cell biology at Vanderbilt School of Medicine.

Dallas Cowboys Owner Jerry Jones Invested In GameSquare. The CEO Explains The Future Of Sports $GAME

Guest: Justin Kenna CEO of GameSquare Holdings, Inc., (NASDAQ: GAME)

Company:

GameSquare Holdings Inc. ($GAME)

Website: https://www.gamesquare.com/

CEO Bio:

Justin Kenna is the CEO of GameSquare Holdings, Inc., (NASDAQ: GAME) (TSXV: GAME) an international esports and gaming company revolutionizing the way brands and game publishers connect with hard-to-reach Millennial and Gen Z audiences. He drives strategic direction, integrating global brands within gaming communities through GameSquare's media agencies, data and analytics solutions, SaaS platforms, esports organizations, and content studio.

A seasoned executive with extensive experience in gaming, digital media, and finance, Kenna was recognized in the Leaders Under 40 Sports Business Awards Class of 2023 and on the 2023 Dallas 500 list of the most powerful and influential CEOs in North Texas. As former CFO of FaZe Clan, he helped grow one of the world's most globally recognized gaming brands, which he then acquired in 2023 at GameSquare. He has also held finance roles at Madison+Vine, Goldman Sachs, Ernst & Young, and Deloitte and belongs to the Institute of Chartered Accountants.

Under his leadership, GameSquare has partnered with over 150 global brands, including Lenovo, Mastercard and Kraft-Heinz, and established collaborations with major sports leagues like the NFL. His efforts have fostered inclusivity in gaming through campaigns with blue chip brands.

Kenna's strategic leadership has attracted prominent investors and board members, including Dallas Cowboys owner Jerry Jones and the Goff Family. Kenna lives in Dallas with his wife and daughter.

Company Bio:

Building the future of sports.

GameSquare's (NASDAQ: GAME) mission is to revolutionize the way brands and game publishers connect with hard-to-reach Gen Z, Gen Alpha, and Millennial audiences.

Our next generation media, entertainment, and technology capabilities drive compelling outcomes for creators and maximize our brand partners' return on investment. Through our purpose-built platform, we provide award winning marketing and creative services, offer leading data and analytics solutions, and amplify awareness through FaZe Clan, one of the most prominent and influential gaming organizations in the world.

With one of the largest gaming media networks in North America, as verified by Comscore, we are reshaping the landscape of digital media and immersive entertainment. GameSquare's largest investors are Dallas Cowboys owner Jerry Jones and the Goff family.

How This CEO Creates & Captures Value Sam Rubin President and CEO LightPath Technologies - $LPTH

Ticker: $LPTH

Website: https://www.lightpath.com/

Guest:

Sam Rubin, President & Chief Executive Officer LightPath Technologies (NASDAQ: LPTH)

Bio:

In Mr. Rubin’s prior senior executive role at Thorlabs, he was responsible for Thorlabs’ Imaging Systems Division, a standalone organization with its own sales and marketing, as well as global responsibility for all of Thorlabs’ Life Science activities.

Among the positions he held at Thorlabs, Mr. Rubin founded and grew Thorlabs’s fast-growing operation in China, and spearheaded Thorlabs’ entry and significant growth in the Life Sciences market. As a member of the senior executive team, Mr. Rubin leads new strategic initiatives for Thorlabs, including new product lines, acquisitions, and growth into new markets. Prior to joining Thorlabs, Mr. Rubin co-founded XLight Photonics, an optical communication startup, which was later sold to a telecommunications private equity firm.

Mr. Rubin holds a Bachelor of Science degree in Electronic Engineering from Ben Gurion University, a Master of Business Administration degree from New York University, Stern School of Business, and is a graduate of the Executive Education, Program for Leadership Development at Harvard Business School.

This CEO is Using LSD To Fight Depression, PMS, and Other Mental Health Conditions – Justin Hanka CEO -Co-Founder Of Mind Bio Therapeutics -CSE-MBIO

This CEO is Using LSD To Fight Depression, PMS, and Other Mental Health Conditions – Justin Hanka CEO -Co-Founder Of Mind Bio Therapeutics -CSE-MBIO

Justin Hanka | Co-founder | Chief Executive Director

MindBio Therapeutics Ltd

Ticker: $MBIO – Canada.

Frankfurt Börse - FRA: WF6

Website:

https://www.mindbiotherapeutics.com/

Bio:

Justin works in investment banking and financing of mergers and acquisitions and particularly he specializes in capital markets transactions and working with technology in the life and health sciences sector.

He is Non-Executive Director of EonX (CSE:EONX), a financial technology company, Non-Executive Chairman of Blackhawk Growth Corp (CSE:BLR), an investment issuer and Non-Executive Director and Chairman of SPARC AI (CSE:SPAI), an engineering company commercializing covert geospatial location and tracking technology for drones.

Justin is Co-Founder and CEO of Hardenbrook Group, a merchant and investment bank and Co-founder and CEO of MindBio Therapeutics (CSE:MBIO), a clinical stage pharma developing psychedelic microdosing formulations to treat depression and is currently dosing in multiple Phase 2B clinical trials. Justin is also Co-founder of Life AI Corp, a life sciences technology company developing AI solutions for longevity and enhancing health and wellness at scale.

Justin’s expertise and interests span the pharmaceutical and life sciences sector, fin-techs, technology that utilizes AI and machine learning methods, banking and insurance, health and wellness, biohacking, anti-ageing and ecommerce.